JP2006501165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501165A5 JP2006501165A5 JP2004510817A JP2004510817A JP2006501165A5 JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5 JP 2004510817 A JP2004510817 A JP 2004510817A JP 2004510817 A JP2004510817 A JP 2004510817A JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- subject
- exposed
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 230000005779 cell damage Effects 0.000 claims 6
- 208000037887 cell injury Diseases 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940126575 aminoglycoside Drugs 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 230000003492 excitotoxic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012825 JNK inhibitor Substances 0.000 description 7
- 229940118135 JNK inhibitor Drugs 0.000 description 6
- 102100023132 Transcription factor Jun Human genes 0.000 description 6
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 3
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 3
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 3
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/165,250 US20030108539A1 (en) | 2000-02-14 | 2002-06-07 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| PCT/IB2003/003094 WO2003103698A1 (en) | 2002-06-07 | 2003-06-09 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009272904A Division JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006501165A JP2006501165A (ja) | 2006-01-12 |
| JP2006501165A5 true JP2006501165A5 (enExample) | 2010-02-18 |
| JP4460445B2 JP4460445B2 (ja) | 2010-05-12 |
Family
ID=29732060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510817A Expired - Lifetime JP4460445B2 (ja) | 2002-06-07 | 2003-06-09 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
| JP2009272904A Withdrawn JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009272904A Withdrawn JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20030108539A1 (enExample) |
| EP (7) | EP1970070A3 (enExample) |
| JP (2) | JP4460445B2 (enExample) |
| AT (2) | ATE417623T1 (enExample) |
| AU (1) | AU2003274820B2 (enExample) |
| CA (1) | CA2488695C (enExample) |
| CY (3) | CY1108847T1 (enExample) |
| DE (2) | DE60316149D1 (enExample) |
| DK (2) | DK1911458T5 (enExample) |
| ES (3) | ES2319454T3 (enExample) |
| HK (1) | HK1207971A1 (enExample) |
| PT (3) | PT2060265E (enExample) |
| SI (1) | SI1776958T1 (enExample) |
| WO (1) | WO2003103698A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| CA2663545A1 (en) | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
| CN103524623A (zh) | 2007-01-19 | 2014-01-22 | 凯制药公司 | 肽组合物的修饰以提高稳定性和递送效率 |
| WO2008154700A1 (en) * | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US20120101046A1 (en) * | 2009-03-30 | 2012-04-26 | Santen Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide |
| JP5457813B2 (ja) * | 2009-12-16 | 2014-04-02 | ルネサスエレクトロニクス株式会社 | Ａｄｐｌｌ回路、半導体装置及び携帯情報機器 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| EP3501521A1 (en) * | 2011-02-18 | 2019-06-26 | Otonomy, Inc. | Prevention of and recovery from drug-induced ototoxicity |
| BR112014013041A2 (pt) * | 2011-11-30 | 2019-09-24 | Xigen Inflammation Ltd | uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| PL3013353T3 (pl) | 2013-06-26 | 2021-09-20 | Xigen Inflammation Ltd. | Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| CN109182250A (zh) * | 2018-09-30 | 2019-01-11 | 山东省立医院 | 一种小鼠耳蜗毛细胞培养方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US817457A (en) * | 1906-01-18 | 1906-04-10 | Kelley M Turner | Head band or support for telephone-receivers. |
| US1447969A (en) * | 1922-05-12 | 1923-03-13 | Brandes Inc C | Telephone head set |
| US4048453A (en) * | 1976-02-11 | 1977-09-13 | Gustave Seidel | Telephone handset support device |
| US4631211A (en) * | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
| DE4005783A1 (de) * | 1990-02-23 | 1991-09-05 | Andreas Suckert | Kopfhalterung fuer telefonhoerer |
| EP0903408A3 (en) * | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| ATE200625T1 (de) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | Leberreservezellen |
| EP0767833A1 (en) * | 1995-04-25 | 1997-04-16 | Baxter International Inc. | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
| BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
| US5689558A (en) * | 1996-03-25 | 1997-11-18 | Osgood; Alan G. | Telephone handset holder |
| US5880261A (en) * | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
| US5828749A (en) * | 1997-04-04 | 1998-10-27 | Brodskiy; Arkadiy | Phone holder kit |
| US6043083A (en) * | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
| EP0897002A3 (en) * | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
| EP0947524A1 (en) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| AU3714499A (en) * | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
| AU755564B2 (en) * | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| WO2000018407A1 (en) * | 1998-09-25 | 2000-04-06 | Cephalon, Inc. | Methods for preventing/treating damage to sensory hair cells and cochlear neurons |
| US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| CA2392615A1 (en) * | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
| ES2386505T3 (es) * | 2000-10-17 | 2012-08-22 | Diatranz Otsuka Limited | Preparación y xenotrasplante de islotes de cerdo |
| DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| CA2442909C (en) * | 2001-04-06 | 2011-11-29 | Thomas Jefferson University | Multimerization of hiv-1 vif protein as a therapeutic target |
-
2002
- 2002-06-07 US US10/165,250 patent/US20030108539A1/en not_active Abandoned
-
2003
- 2003-06-09 EP EP07023486A patent/EP1970070A3/en not_active Ceased
- 2003-06-09 EP EP08021394.5A patent/EP2060265B1/en not_active Expired - Lifetime
- 2003-06-09 DK DK07016361.3T patent/DK1911458T5/da active
- 2003-06-09 EP EP06019172.3A patent/EP1776958B9/en not_active Expired - Lifetime
- 2003-06-09 AT AT06019172T patent/ATE417623T1/de active
- 2003-06-09 PT PT80213945T patent/PT2060265E/pt unknown
- 2003-06-09 CA CA2488695A patent/CA2488695C/en not_active Expired - Lifetime
- 2003-06-09 EP EP14001780.7A patent/EP2845603A1/en not_active Withdrawn
- 2003-06-09 EP EP07016361.3A patent/EP1911458B9/en not_active Expired - Lifetime
- 2003-06-09 AT AT03740977T patent/ATE372125T1/de not_active IP Right Cessation
- 2003-06-09 DE DE60316149T patent/DE60316149D1/de not_active Expired - Lifetime
- 2003-06-09 DK DK06019172.3T patent/DK1776958T5/da active
- 2003-06-09 ES ES06019172T patent/ES2319454T3/es not_active Expired - Lifetime
- 2003-06-09 ES ES08021394.5T patent/ES2439950T3/es not_active Expired - Lifetime
- 2003-06-09 WO PCT/IB2003/003094 patent/WO2003103698A1/en not_active Ceased
- 2003-06-09 PT PT06019172T patent/PT1776958E/pt unknown
- 2003-06-09 PT PT70163613T patent/PT1911458E/pt unknown
- 2003-06-09 EP EP03740977A patent/EP1511507B1/en not_active Expired - Lifetime
- 2003-06-09 DE DE60325429T patent/DE60325429D1/de not_active Expired - Lifetime
- 2003-06-09 JP JP2004510817A patent/JP4460445B2/ja not_active Expired - Lifetime
- 2003-06-09 ES ES07016361.3T patent/ES2473274T3/es not_active Expired - Lifetime
- 2003-06-09 SI SI200331484T patent/SI1776958T1/sl unknown
- 2003-06-09 EP EP12001707.4A patent/EP2532357A3/en not_active Withdrawn
- 2003-06-09 AU AU2003274820A patent/AU2003274820B2/en not_active Ceased
-
2009
- 2009-03-05 CY CY20091100251T patent/CY1108847T1/el unknown
- 2009-11-30 JP JP2009272904A patent/JP2010053136A/ja not_active Withdrawn
-
2013
- 2013-12-11 CY CY20131101120T patent/CY1114715T1/el unknown
-
2014
- 2014-04-15 CY CY20141100286T patent/CY1115331T1/el unknown
-
2015
- 2015-09-02 HK HK15108602.6A patent/HK1207971A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501165A5 (enExample) | ||
| ES2732252T3 (es) | Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante | |
| CZ20014289A3 (cs) | Nové pouľití sloučenin jako antibakteriálních činidel | |
| NZ527157A (en) | Compositions for delivering bisphosphonates | |
| CA2442909A1 (en) | Multimerization of hiv-1 vif protein as a therapeutic target | |
| CA2488695A1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
| JP2018502836A5 (enExample) | ||
| BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
| CA2332817A1 (en) | Il-6 antagonist peptides | |
| WO2010107476A1 (en) | Inhibiting gsnor | |
| CN102016980A (zh) | 用于治疗癌症的胰岛素样生长因子结合蛋白7 | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| JP2015514756A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| RU2016110153A (ru) | Новые пептиды и их аналоги для применения при лечении мукозита полости рта | |
| ATE383850T1 (de) | Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung | |
| JP2005506345A5 (enExample) | ||
| JP2009530359A (ja) | 腫瘍成長の阻害 | |
| JP2025027020A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| AU2008335840A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) | |
| JP2021500409A5 (enExample) | ||
| CN100418532C (zh) | 治疗多种疾病的NF-κB化合物抑制剂 | |
| CA2374681A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| JP2019108277A5 (enExample) | ||
| WO2016071431A9 (en) | A combination for cancer therapy |